APRE logo

APREA THERAPEUTICS INC

APRENASDAQ
🏆 #4931 by market capEarnings Nov 10US Equity
$0.54▲ $0.02 (+4.83%)
Market closed · at close
🔔
Track APRE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.8%
7d▼ 1.5%
14d▼ 12.4%
30d▼ 30.5%
ytd▼ 37.0%
1y▼ 62.7%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.51 – $0.54
52-Week Range
$0.41 – $1.49
Volume (shares)
147,494
Avg Volume (shares)
—
Shares Outstanding
12.6M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-0.5
P/S Ratio
0.0x
EPS (TTM)
$-0.23
Dividend Yield
0.00%
Dilution (1yr)
+29.1%
APRE logo

APREA THERAPEUTICS INC

APRE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-523.2%▼ −629.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −7.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▼ −5.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.7M▲ +29.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15M▼ −$8M YoY
StockOtter · stockotter.space

About APREA THERAPEUTICS INC

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·12d ago

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of tar

GlobeNewsWire·23d ago

Aprea Therapeutics to Present at October Conferences

Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (Oc

GlobeNewsWire·Sep 22

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of ta

GlobeNewsWire·Sep 10

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of ta

GlobeNewsWire·Aug 28

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents

GlobeNewsWire·Aug 12

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances